

Proposed Project Scope

Nivolumab with doxorubicin, vinblastine and dacarbazine (AVD) for previously untreated stage III or IV Hodgkin Lymphoma

Date: November 2024

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of nivolumab with doxorubicin, vinblastine, and dacarbazine (AVD) for previously untreated stage III or IV Hodgkin Lymphoma.

Table I: Policy Questions

Item	Policy Question
1	Should nivolumab be publicly reimbursed with AVD in previously untreated stage III or IV Hodgkin Lymphoma?

Table II: Products Available in Canada

Product	Manufacturer
Nivolumab	Bristol-Myers Squibb (BMS)

Project Description

Table III: Project Scope

Criteria	Description
Population	Adults and adolescents (12 years and older) with previously untreated stage III or IV Hodgkin Lymphoma
Intervention(s)	Nivolumab and AVD
Comparators	Brentuximab vedotin and AVD ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) Comparators for the pediatric population: BV-AVEPC ABVE-PC
Outcomes	Progression-free survival Overall survival Event-free survival Adverse events Quality of life

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of nivolumab with AVD in previously untreated stage III or IV Hodgkin Lymphoma?
2	What are the harms associated with nivolumab with AVD in previously untreated stage III or IV Hodgkin Lymphoma?
3	What is the expected cost of nivolumab with AVD in previously untreated stage III or IV Hodgkin Lymphoma vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

Status of the Document

This proposed project scope is being posted for information.